Advertisement


Muhit Özcan, MD, on DLBCL: Early Results on Zilovertamab Vedotin

2023 ASCO Annual Meeting

Advertisement

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses phase II findings from the waveLINE-004 study. It showed that the antibody-drug conjugate zilovertamab vedotin had clinically meaningful antitumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who experienced disease progression after, or have been ineligible for, autologous stem cell transplantation and/or chimeric antigen receptor T-cell therapy (Abstract 7531).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Muhit Özcan, MD: Treatment options are limited for patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for or who have disease progression after autologous stem cell transplant and CAR T-cell therapy. ROR1 is an oncofetal transmembrane protein that's expressed in various hematological malignancies, including diffuse large B-cell lymphomas. Zilovertamab vedotin is an antibody drug conjugate compressing an anti-ROR1 monoclonal antibody plus a cleavable linker and the anti-microtubule cytotoxin monomethyl auristatin E. Here, we present early results from the single-arm, open label, phase-II waveLINE-004 study, which is designed to evaluate the efficacy and safe zilovertamab vedotin in patients with relapsed or refractory diffused large B-cell lymphoma who are ineligible for or who have disease progression after autologous stem cell transplant or after CAR T-cell therapy. Patients in waveLINE-004 received zilovertamab vedotin at 2.5 milligram per kilogram intravenously every three weeks. The primary endpoint was objective response rate, and the secondary endpoint was safety and tolerability. Safety was evaluated in all patients who received at least one cycle of study treatment, and efficacy was evaluated in all patients who received at least one dose of study treatment and had at least three months of follow-up. At the data cut-off, 40 patients had received treatment. The median age of patients was 68 years, 60% of patients had received three or more prior lines of therapy, 25% of patients had undergone prior stem cell transplant, and 28% of them had undergone prior CAR T-cell therapy. The objective response rate among the 20 patients with at least three months follow up was 30%, with two patients achieving a complete response and four patients achieving a partial response. An additional five patients had stable disease for a disease control rate of 55%, 95% confidence interval, 31.5 to 76.9%. Five patients had progressive disease and four patients could not be assessed. When change in target lesion size was evaluated, 13 or 20 patients had any reduction from baseline, and seven patients had a reduction in target lesion size of 50% or more. Treatment-related adverse events of any grade occurred in 70% of patients, most commonly diarrhea in 23, anemia in 20, neutropenia in 18, and neutrophil count decrease in 18% of patients. Grade 3 or 4 treatment-related adverse events occurred in 40% of patients and no that's due to treatment-related adverse events occurred. One patient discontinued treatment because of grade 3 treatment-related ketoacidosis. Treatment-related peripheral neuropathy occurred in 15% of patients over grade 1 or 2. No infusion-related reactions or treatment-related tumor lysis syndrome occurred. In summary, these earlier results from waveLINE-004 showed that zilovertamab vedotin had clinically-meaningful antitumor activity and manageable safety in patients with relapsed or refractory diffused large B-cell lymphoma who are ineligible for or who have had disease progression after autologous stem cell transplantation or after CAR T-cell therapy. These results support the continued investigation of zilovertamab vedotin in patients with relapsed or refractory diffused large B-cell lymphoma.

Related Videos

Gynecologic Cancers

Bobbie J. Rimel, MD, and Mansoor R. Mirza, MD, on Endometrial Cancer: Patient-Reported Outcomes With Dostarlimab, Carboplatin, and Paclitaxel

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Mansoor R. Mirza, MD, of Denmark’s Rigshospitalet and Copenhagen University Hospital, discuss new findings on dostarlimab-gxly plus carboplatin/paclitaxel, which improved progression-free survival while maintaining health-related quality of life, further supporting its use as a standard of care in primary advanced or recurrent endometrial cancer (Abstract 5504).

Issues in Oncology

Carmen E. Guerra, MD, MSCE, on Diversity, Equity, and Inclusion in Clinical Trials: Expert Commentary

Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses three key abstracts presented at ASCO: strategies to increase accrual of underrepresented populations in Alliance NCTN trials, how patient-clinician education can strengthen partnerships and improve diversity in breast and lung cancer trials, and mediators of racial and ethnic inequities in clinical trial participation among U.S. patients with cancer from 2011 to 2022 (Abstracts 6509, 6510, 6511).

Gynecologic Cancers

Bobbie J. Rimel, MD, and Kathleen N. Moore, MD, on Ovarian Cancer: New Findings on Mirvetuximab Soravtansine vs Chemotherapy

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Kathleen N. Moore, MD, of the Stephenson Oklahoma Cancer Center at the University of Oklahoma, discuss phase III results from the MIRASOL trial, which showed that mirvetuximab soravtansine-gynx prolonged overall survival vs investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer with high folate receptor-alpha expression. The findings suggest a new standard of care for this disease (Abstract LBA5507).

Leukemia

LaQuisa C. Hill, MD, on Relapsed or Refractory T-ALL: New Data on CD5 CAR T Cells

LaQuisa C. Hill, MD, of Baylor College of Medicine, Houston Methodist Hospital, discusses study findings showing that CD5 chimeric antigen receptor (CAR) T cells may induce clinical responses in heavily treated patients with relapsed or refractory T-cell acute lymphoblastic leukemia. Manufacturing CD5 CAR T cells with tyrosine kinase inhibitors seemed to improve their potency and antitumor activity (Abstract 7002).

Lung Cancer
Genomics/Genetics

Narjust Florez, MD, and Ferdinandos Skoulidis, MD, PhD, on NSCLC: Findings on Sotorasib vs Docetaxel in the CodeBreaK 200 Trial

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Ferdinandos Skoulidis, MD, PhD, of The University of Texas MD Anderson Cancer Center, discuss results of a biomarker subgroup analysis, showing that sotorasib demonstrated consistent clinical benefit vs docetaxel in all molecularly defined subgroups of patients with pretreated KRAS G12C–mutated advanced non–small cell lung cancer (NSCLC). Although no predictive biomarkers were confirmed, novel hypothesis-generating signals were observed (Abstract 9008).

Advertisement

Advertisement




Advertisement